Recursion Pharmaceuticals, Inc. (RXRX) stock surged 12.63% in the pre-market trading session on Tuesday, following Nvidia's disclosure that it maintained its investment in the medical AI company during the fourth quarter of 2024.
According to regulatory filings, Nvidia revealed that it held on to its stake in Recursion Pharmaceuticals, a move that has bolstered investor confidence in the company's prospects. This sustained backing from the tech giant has fueled the pre-market rally, as traders view Nvidia's continued investment as a vote of confidence in Recursion Pharmaceuticals' potential.
The positive sentiment surrounding Recursion Pharmaceuticals was further amplified by Berkshire Hathaway's recent investment activities, including taking a new position in Constellation Brands, a move that has injected optimism into the broader market.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.